185 related articles for article (PubMed ID: 37838774)
101. The Autoimmune Lymphoproliferative Syndrome with Defective FAS or FAS-Ligand Functions.
Rieux-Laucat F; Magérus-Chatinet A; Neven B
J Clin Immunol; 2018 Jul; 38(5):558-568. PubMed ID: 29911256
[TBL] [Abstract][Full Text] [Related]
102. Characterizing the regulatory Fas (CD95) epitope critical for agonist antibody targeting and CAR-T bystander function in ovarian cancer.
Mondal T; Gaur H; Wamba BEN; Michalak AG; Stout C; Watson MR; Aleixo SL; Singh A; Condello S; Faller R; Leiserowitz GS; Bhatnagar S; Tushir-Singh J
Cell Death Differ; 2023 Nov; 30(11):2408-2431. PubMed ID: 37838774
[TBL] [Abstract][Full Text] [Related]
103. A Critical Role for Fas-Mediated Off-Target Tumor Killing in T-cell Immunotherapy.
Upadhyay R; Boiarsky JA; Pantsulaia G; Svensson-Arvelund J; Lin MJ; Wroblewska A; Bhalla S; Scholler N; Bot A; Rossi JM; Sadek N; Parekh S; Lagana A; Baccarini A; Merad M; Brown BD; Brody JD
Cancer Discov; 2021 Mar; 11(3):599-613. PubMed ID: 33334730
[TBL] [Abstract][Full Text] [Related]
104. A homozygous Fas ligand gene mutation in a patient causes a new type of autoimmune lymphoproliferative syndrome.
Del-Rey M; Ruiz-Contreras J; Bosque A; Calleja S; Gomez-Rial J; Roldan E; Morales P; Serrano A; Anel A; Paz-Artal E; Allende LM
Blood; 2006 Aug; 108(4):1306-12. PubMed ID: 16627752
[TBL] [Abstract][Full Text] [Related]
105. CD30-Redirected Chimeric Antigen Receptor T Cells Target CD30
Hong LK; Chen Y; Smith CC; Montgomery SA; Vincent BG; Dotti G; Savoldo B
Cancer Immunol Res; 2018 Oct; 6(10):1274-1287. PubMed ID: 30087115
[TBL] [Abstract][Full Text] [Related]
106. On the role and significance of Fas (Apo-1/CD95) ligand (FasL) expression in immune privileged tissues and cancer cells using multiple myeloma as a model.
Greil R; Egle A; Villunger A
Leuk Lymphoma; 1998 Nov; 31(5-6):477-90. PubMed ID: 9922038
[TBL] [Abstract][Full Text] [Related]
107. Revisiting autoimmune lymphoproliferative syndrome caused by Fas ligand mutations.
Maccari ME; Schneider P; Smulski CR; Meinhardt A; Pinto F; Gonzalez-Granado LI; Schuetz C; Sica MP; Gross M; Fuchs I; Kury P; Heeg M; Vocat T; Willen L; Thomas C; Hühn R; Magerus A; Lorenz M; Schwarz K; Rieux-Laucat F; Ehl S; Rensing-Ehl A
J Allergy Clin Immunol; 2023 May; 151(5):1391-1401.e7. PubMed ID: 36621650
[TBL] [Abstract][Full Text] [Related]
108. Autoinhibitory structure of preligand association state implicates a new strategy to attain effective DR5 receptor activation.
Du G; Zhao L; Zheng Y; Belfetmi A; Cai T; Xu B; Heyninck K; Van Den Heede K; Buyse MA; Fontana P; Bowman M; Lin LL; Wu H; Chou JJ
Cell Res; 2023 Feb; 33(2):131-146. PubMed ID: 36604598
[TBL] [Abstract][Full Text] [Related]
109. Targeting NaPi2b in ovarian cancer.
Banerjee S; Drapkin R; Richardson DL; Birrer M
Cancer Treat Rev; 2023 Jan; 112():102489. PubMed ID: 36446254
[TBL] [Abstract][Full Text] [Related]
110. cFLIP suppression and DR5 activation sensitize senescent cancer cells to senolysis.
Wang L; Jin H; Jochems F; Wang S; Lieftink C; Martinez IM; De Conti G; Edwards F; de Oliveira RL; Schepers A; Zhou Y; Zheng J; Wu W; Zheng X; Yuan S; Ling J; Jastrzebski K; Santos Dias MD; Song JY; Celie PNH; Yagita H; Yao M; Zhou W; Beijersbergen RL; Qin W; Bernards R
Nat Cancer; 2022 Nov; 3(11):1284-1299. PubMed ID: 36414711
[TBL] [Abstract][Full Text] [Related]
111. Secreted Fas Decoys Enhance the Antitumor Activity of Engineered and Bystander T Cells in Fas Ligand-Expressing Solid Tumors.
Bajgain P; Torres Chavez AG; Balasubramanian K; Fleckenstein L; Lulla P; Heslop HE; Vera J; Leen AM
Cancer Immunol Res; 2022 Nov; 10(11):1370-1385. PubMed ID: 36122411
[TBL] [Abstract][Full Text] [Related]
112. Differential Expression of Proteins in an Atypical Presentation of Autoimmune Lymphoproliferative Syndrome.
Delgadillo DM; Céspedes-Cruz AI; Ríos-Castro E; Rodríguez Maldonado MG; López-Nogueda M; Márquez-Gutiérrez M; Villalobos-Manzo R; Ramírez-Reyes L; Domínguez-Fuentes M; Tapia-Ramírez J
Int J Mol Sci; 2022 May; 23(10):. PubMed ID: 35628184
[TBL] [Abstract][Full Text] [Related]
113. Engineering adoptive T cell therapy to co-opt Fas ligand-mediated death signaling in ovarian cancer enhances therapeutic efficacy.
Anderson KG; Oda SK; Bates BM; Burnett MG; Rodgers Suarez M; Ruskin SL; Greenberg PD
J Immunother Cancer; 2022 Mar; 10(3):. PubMed ID: 35264436
[TBL] [Abstract][Full Text] [Related]
114. ALPS, FAS, and beyond: from inborn errors of immunity to acquired immunodeficiencies.
Consonni F; Gambineri E; Favre C
Ann Hematol; 2022 Mar; 101(3):469-484. PubMed ID: 35059842
[TBL] [Abstract][Full Text] [Related]
115. A patch of positively charged residues regulates the efficacy of clinical DR5 antibodies in solid tumors.
Shivange G; Mondal T; Lyerly E; Bhatnagar S; Landen CN; Reddy S; Kim J; Doan B; Riddle P; Tushir-Singh J
Cell Rep; 2021 Nov; 37(5):109953. PubMed ID: 34731630
[TBL] [Abstract][Full Text] [Related]
116. TCR β chain-directed bispecific antibodies for the treatment of T cell cancers.
Paul S; Pearlman AH; Douglass J; Mog BJ; Hsiue EH; Hwang MS; DiNapoli SR; Konig MF; Brown PA; Wright KM; Sur S; Gabelli SB; Li Y; Ghiaur G; Pardoll DM; Papadopoulos N; Bettegowda C; Kinzler KW; Zhou S; Vogelstein B
Sci Transl Med; 2021 Mar; 13(584):. PubMed ID: 33649188
[TBL] [Abstract][Full Text] [Related]
117. Comparative analysis of assays to measure CAR T-cell-mediated cytotoxicity.
Kiesgen S; Messinger JC; Chintala NK; Tano Z; Adusumilli PS
Nat Protoc; 2021 Mar; 16(3):1331-1342. PubMed ID: 33589826
[TBL] [Abstract][Full Text] [Related]
118.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
119.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
120.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
